TICKERNERD
Menu
ZYBTZYBTHealthcare · Drug Manufacturers - Specialty & Generic

ZYBT Stock Forecast: Zhengye Biotechnology Holding Ltd. Price Predictions for 2026-2027

Last close, 28 Oct 2026
$1.42
−1.39% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 49 of 100 as at 28 Oct 2026 — in the lower half.

Market cap
$68.2M
Ticker Nerd rank
49/ 100
Median analyst target
—
Analysts covering
—
Total return, dividends reinvested
1W
−2.7%
1M
+9.2%
YTD
+23.5%
1Y
−34.9%
From 52W high
−76.9%
From 52W low
+119.8%
$0.65
$6.15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ZYBT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Zhengye Biotechnology Holding Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
49/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
96
Issuance
83
Size
82
Quality
47
Value
44
Momentum
38
Revisions
25
Volatility
25
Growth
21

Accruals (96): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (21): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ZYBT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ZYBT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00$6.00Jan 26Apr 26Jul 26Oct 26ZYBT

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ZYBT appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ZYBT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 28 Oct 2026, Zhengye Biotechnology Holding Ltd. returned −34.9% against +13.6% for the S&P 500, dividends included.

ZYBT vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150200250300Jan 26Apr 26Jul 26Oct 26ZYBTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ZYBT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Zhengye Biotechnology Holding Ltd. (ZYBT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
63.3×

Cheaper than 11% of US stocks

Price / sales
0.6×

Cheaper than 78% of US stocks

Price / book
1.8×

Cheaper than 46% of US stocks

EV / EBITDA
−3.3×

Cheaper than 77% of US stocks

Growth & margins
Revenue growth (YoY)
−40.9%

Higher than 7% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−77.0%

Higher than 15% of US stocks

Net margin
−60.0%

Higher than 9% of US stocks

Returns & dividend
Return on equity
−25.2%

Higher than 29% of US stocks

Return on assets
−9.5%

Higher than 27% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Zhengye Biotechnology Holding Ltd. (ZYBT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Zhengye Biotechnology Holding Ltd. has a market value of $68.2M and an enterprise value of $22.2M.

  • Shares outstanding: 47.4M.

  • Trailing P/E: 63.3×.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Zhengye Biotechnology Holding Ltd. employs 269 people.

market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

ZYBT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
ZYBTZhengye Biotechnology Holding Ltd.$68.2M49
SCYXSCYNEXIS, Inc.$39.2M41
CTORCitius Oncology, Inc.$53.6M40
TLPHTalphera, Inc.$54.6M37
IXHLIncannex Healthcare, Inc.$32.4M24
RMTIRockwell Medical, Inc.$28.9M56
INCRInterCure Ltd.$64.8M—

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Zhengye Biotechnology Holding Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ZYBT news & analysis

Zhengye Biotechnology Holding Limited Regains Compliance with Nasdaq Bid Price Requirement

GlobeNewsWire · 6 Aug 2026positive

Zhengye Biotechnology Holding Limited announced that on August 5, 2026, it received a letter from Nasdaq informing the company it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). The company had previously been notified on May 29, 2026 that its Class A ordinary shares' closing bid price had fallen below $1.00 for 30 consecutive business days.

Why it matters — ZYBT watchers would care because regaining compliance removes the risk of delisting from Nasdaq related to the bid price deficiency.

FAQ

Frequently asked questions about ZYBT stock

How does Ticker Nerd's model rank ZYBT?

As at 28 Oct 2026, Zhengye Biotechnology Holding Ltd. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (96 of 100).

What is the ZYBT stock forecast for 2030?

No analyst covering Zhengye Biotechnology Holding Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZYBT are extrapolating price history, which says nothing about the business.

How has ZYBT stock performed over the past year?

Zhengye Biotechnology Holding Ltd. returned -34.9% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Zhengye Biotechnology Holding Ltd. do?

Zhengye Biotechnology Holding Ltd. Class A Ordinary Shares represents the equity of Zhengye Biotechnology Holding Limited, a veterinary vaccine manufacturer focused on research, development, manufacturing, and sales of vaccines for livestock and other animals.

What is the latest news on ZYBT?

The most recent item we track (GlobeNewsWire, 6 Aug 2026): "Zhengye Biotechnology Holding Limited Regains Compliance with Nasdaq Bid Price Requirement". Zhengye Biotechnology Holding Limited announced that on August 5, 2026, it received a letter from Nasdaq informing the company it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). The company had previously been notified on May 29, 2026 that its Class A ordinary shares' closing bid price had fallen below $1.00 for 30 consecutive business days.

Company

About Zhengye Biotechnology Holding Ltd.

Zhengye Biotechnology Holding Ltd. Class A Ordinary Shares represents the equity of Zhengye Biotechnology Holding Limited, a veterinary vaccine manufacturer focused on research, development, manufacturing, and sales of vaccines for livestock and other animals. The company’s product portfolio includes vaccines for swine, cattle, goats, sheep, poultry, and dogs, supporting disease prevention across animal health markets in China. Its business is centered on serving veterinary and agricultural needs through a range of monovalent, polyvalent, and combined vaccine offerings. Zhengye Biotechnology Holding Ltd. operates in the biotechnology and health technology sectors, where it plays a role in supplying immunization products used by veterinarians, farms, and livestock producers. The Class A Ordinary Shares are part of the company’s dual-class share structure and reflect its ordinary equity interests.

269 employees · China · https://www.jlzybio.com